Finoriq research workspace
Aligos Therapeutics, Inc. (ALGS) News
Aligos Therapeutics, Inc. also develops pevifoscorvir sodium, a capsid assembly modulator, which is in. Review ALGS recent headlines, source links, and company news on Finoriq.
Company Snapshot
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
- Company
- Aligos Therapeutics, Inc. (ALGS)
- Ticker
- ALGS
- Market Cap
- $32.5M
- Latest Price
- $5.25
- Industry
- Biotech & Pharma
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.